ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M
ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M
Size of the Fully Guaranteed Capital Increase with subscription rights: EUR 32.7m
Subscription ratio: 1 new share for every 5 existing shares
Subscription price: 2.65 euro per new share
Subscription Rights Trading Period: from May 29 to June 11, 2026 included
Aurobindo Pharma to expand manufacture of generic formulations in France
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
Cartesian secures funding to 'accelerate' launch; Editas sells $125M in stock
ATB Cormark Capital Markets Sticks to Their Buy Rating for Abaxx Technologies Inc (ABXX)
Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment…
ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025
La compañía cae un 4% en Bolsa tras fijar un precio de emisión de 2,35 euros por acción, cuando ahora cotiza a más de 3
Il titolo ha visto un balzo fino al +31% sull’ipotesi di un’offerta del gruppo statunitense da 15 miliardi di euro
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a…
The operation raised €60 million, a third of which came from Sanofi, which will hold 13.9% of the company's shares.
